02359.HK
WuXi AppTec Co., Ltd.
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 191.10
−0.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 53.5B | 45.5B | 39.2B | 40.3B | 39.4B |
| Cost of Revenue | 25.7B | 23.8B | 23.0B | 23.8B | 24.7B |
| Gross Profit | 27.7B | 21.7B | 16.3B | 16.6B | 14.7B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 1.1B | 1.2B | 1.4B | 1.6B |
| SG&A Expense | (60.3M) | 930.6M | 969.7M | 1.1B | 1.7B |
| General & Admin Expense | 677.2M | 680.7M | 759.2M | 905.6M | 927.2M |
| Selling & Marketing Expense | 239.6M | 250.0M | 210.5M | 188.0M | 731.6M |
| Other Expenses | 3.6B | 2.6B | 2.5B | 2.2B | 1.7B |
| Total Operating Expenses | 4.8B | 4.6B | 4.7B | 4.7B | 4.9B |
| Cost and Expenses | 30.5B | 28.5B | 27.7B | 28.5B | 29.6B |
| Operating Income (EBIT) | 23.0B | 17.0B | 11.6B | 11.9B | 10.7B |
| Non-Operating | |||||
| Interest Income | 534.9M | 938.0M | 626.8M | 444.5M | 221.9M |
| Interest Expense | 263.6M | 306.5M | 216.0M | 74.8M | 185.9M |
| Net Interest Income | 271.0M | 631.5M | 386.1M | 369.6M | 36.1M |
| Other Non-Op Income/Expense | 4.5B | 6.9B | (40.4M) | (40.3M) | (33.8M) |
| Non-Operating Income (excl Interest) | (4.4B) | (7.2B) | (175.7M) | (13.3M) | (73.7M) |
| EBT (Pre-Tax Income) | 27.5B | 23.9B | 11.5B | 11.8B | 10.6B |
| Income Tax Expense | 5.7B | 4.6B | 2.0B | 2.1B | 1.7B |
| Bottom Line | |||||
| Net Income | 21.6B | 19.2B | 9.5B | 9.6B | 8.8B |
| Earnings from Cont. Ops | 21.7B | 19.3B | 9.6B | 9.7B | 8.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 21.6B | 19.2B | 9.5B | 9.6B | 8.8B |
| Per Share | |||||
| Basic EPS | HK$7.52 | HK$6.70 | HK$3.28 | HK$3.24 | HK$3.15 |
| Diluted EPS | HK$7.43 | HK$6.61 | HK$3.26 | HK$3.24 | HK$3.10 |
| Revenue Per Share | HK$18.64 | HK$15.90 | HK$13.55 | HK$13.61 | HK$13.85 |
| Shares | |||||
| Basic Shares Outstanding | 2.9B | 2.9B | 2.9B | 3.0B | 2.8B |
| Diluted Shares Outstanding | 2.9B | 2.9B | 2.9B | 3.0B | 2.8B |
| Profitability Metrics | |||||
| EBITDA | 27.3B | 27.7B | 14.5B | 14.2B | 12.4B |
| D&A | — | 3.5B | 2.8B | 2.3B | 1.7B |
| EBIT | 27.3B | 24.2B | 11.8B | 11.9B | 10.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026